Find a Phase 1 clinical trial

The table below shows a list of the Experimental Cancer Medicine Team's currently recruiting phase I clinical trials. The arrow links will guide you to clinicaltrials.gov. This is an external public domain database showing clinical trials from around the world.

If you are a patient and you are interested in taking part in a clinical trial listed below, please talk to your oncologist or doctor about the trial you are interested in. We cannot accept nor respond to direct patient requests to participate on a clinical trial. If you are a patient you must be referred to us from your treating physician.

Oncologists working at external sites should contact centralregistration@christie.nhs.uk

If you are an Oncologist from within The Christie you are able to use this referral form to refer patients.

 

Target mechanism of investigative drug

 

Title of clinical trial

 

Hyperlink

 

INCB001158 (Arginase inhibitor)

 

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors

 

 

Mesothelin-targeting antibody-drug conjugate

 

Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies

 

 

DARWIN 1

 

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

 

Contact ECMT enquiries

 

DARWIN 2

 

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWIN II) - A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis

 

Contact ECMT enquiries

 

INC2108

 

A multicenter, open label, phase 1 dose escalation study to evaluate the pharmacokinetics, safety, and tolerability of INC280 tablet formulation with food in patients with CMet dysregulated advanced solid tumors

 

 

 

HuMax®-AXL-ADC

 

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax®-AXL-ADC) in patients with solid tumors

 

 

 

anti-PD-L1 / TGFβ-Trap molecule

 

A Phase 1, open label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetcs, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumours and expansion to selected indications

 

 

 

Anti-PDL-1

 

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY)

 

 

 

oral pan-RAF inhibitor in comb. with paclitaxel

 

A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic Malignancies

 

 

 

oral HSP90 inhibitor

 

A Phase I Study Evaluating TAS-116 in Patients With Advanced Solid Tumors

 

 

alpha folate receptor targeted TS inhibitor

 

A Phase I trial of ONX-0801 (a novel α-folate receptor-mediated thymidylate synthase inhibitor) exploring once weekly and alternate week dosing regimens in patients with solid tumours

 

 

 

ATM kinase inhibitor

 

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)

 

 

 

 

PTEN-deficient/Mutated or PIK3CB Mutated Advanced Solid Malignancies

 

A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient/Mutated or PIK3CB Mutated Advanced Solid Malignancies, With Expansion to Assess the Pharmacodynamic Activity of AZD8186

 

 

 

 

Non-CTIMP

 

Tumour Characterisation to Guide Experimental Targeted Therapy

 

 

Contact ECMT enquiries

 

PanRaf Inhibitor (CCT3833)

 

A Phase 1, First in Man, Dual Centre, Open-label Dose Escalation Study With Expansion to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CCT3833 (BAL3833), a panRAF Inhibitor, Given Orally in Patients With Advanced Solid Tumours, Including Metastatic Melanoma

 

 

 

ATR / PI3K inhibitor (AZD6738) in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents

 

A Modular Phase I, Open-Label, Multicentre Study
to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD6738 in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies

 

 

 

TAS3681

 

A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability, and Pharmacokinetic Study of TAS3681 in Patients with Metastatic Castration Resistant Prostate Cancer

 

 

 

PEN221

 

A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with advanced gastroenteropancreatic or lung neuroendocrine tumors or advanced small-cell lung cancer or other advanced cancers expressing somatostatin receptor 2

 

 

 

PDR2102

 

A phase Ib, multi-center, open-label study of PDR001 in combination with LCL161, panobinostat or everolimus in patients with advanced/metastatic CRC, TNBC or NSCLC

 

 

 

WEE-1 inhibitor

 

A Randomised, Open-label, Phase I Study to Determine the Effect of Formulation and Food on the Pharmacokinetics of AZD1775 After Oral Dosing of a Capsule Formulation in Patients with Advanced Solid Tumours

 

 

 

RXC004 (PORCN inhibitor)

 

A Modular, Multi-Arm, Multi-Part, Phase I/IIa, Adaptive Design Study To Evaluate The Safety And Tolerability Of RXC004, Alone And In Combination With Anti-Cancer Treatments, In Patients With Advanced Malignancies

 

Contact ECMT enquiries

 

TRIBE

 

TRIBE; Tyrosine Kinase Inhibitor (TKI) therapy in Renal Cell Carcinoma: Immune Biomarker Evaluation

 

Contact ECMT enquiries

 

PROACT

 

PROACT: Patient Reported Opinions About Clinical Tolerability.
Empowering patients participating in early clinical studies and providing a way for them to directly contribute to drug development on their own terms.

 

Contact ECMT enquiries

 

IDO1 inhibitor

 

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Selected Advanced Cancers (INCB24360-204)

 

 

 

SRA737 (CHK1 inhibitor)

 

A phase 1 trial of SRA737 (a chk1 inhibitor) administered orally in subjects with advanced cancer.

 

 

 

E7386 (Wnt/ β catenin inhibitor)

 

An Open-Label Multicenter Phase 1 study of E7386 in Subjects with Selected Advanced Neoplasms

 

 

 

BGB324 (AXL inhibitor)

 

Phase II study of BGB324 in combination with Pembrolizumab in patients with previously treated advanced adenocarcinoma of the lung

 

 

 

CX-072 (PD-L1)

 

An open label, dose finding and proof of concept study of the PD-L1 probodyTM therapeutic, C-072, as monotherapy and in combination with Yervoy (Ipilimumab) or with Zelboraf (Vemurafenib) in subjects with advanced or recurrent solid tumours or lymphomas.

 

 

 

JNJ-63723283 (Anti-PDL-1)

 

A first-in-human, open-label, 2-part, phase I/II study to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of JNJ-63723283, an anti-PD-1 antibody, in subjects with advanced cancers

 

 

 

GEN 701 (HuMax-TF-ADC)

 

First-in-human, dose-escalating safety study of tissue specific antibody drug conjugate (HuMax-TF-ADC) in patients with locally advanced and/or metastatic solid tumours known to express tissue factor.

 

 

 

SYD985

 

A two part first-in-human phase I study (with expanded cohorts) with the antibody-drug conjugate SYD985 to evaluate the safety, pharmacokinetics and efficacy in patients with locally advanced or metastatic solid tumours.

 

 

 

STARTRK-2 (NTRK1/2/3, ROS1, or ALK Gene Rearrangements)

 

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

 

 

 

CT7001 (CDK7 inhibitor)

 

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of CT7001 alone or in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Solid Malignancies

 

 

 

OMO-1 (MET inhibitor)

 

A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies

 

 

 

AZD4785 (antisense oligonucleotide (ASO))

 

A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD4785 in Patients with Advanced Solid Tumours Where KRAS May Be an Important Driver of Tumour Survival

 

 

 

PEACE Trial

 

The PEACE (Posthumous tissuE donAtion in CancEr) Study

 

Contact ECMT enquiries

;